These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 8622038

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group.
    Bunn PA, Crowley J, Kelly K, Hazuka MB, Beasley K, Upchurch C, Livingston R, Weiss GR, Hicks WJ, Gandara DR.
    J Clin Oncol; 1995 Jul; 13(7):1632-41. PubMed ID: 7602352
    [Abstract] [Full Text] [Related]

  • 3. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
    Palmeri S, Leonardi V, Danova M, Porta C, Ferrari S, Fincato G, Citarrella P.
    Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
    [Abstract] [Full Text] [Related]

  • 4. Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer.
    Jones SE, Schottstaedt MW, Duncan LA, Kirby RL, Good RH, Mennel RG, George TK, Snyder DA, Watkins DL, Denham CA, Hoyes FA, Rubin AS.
    J Clin Oncol; 1996 Nov; 14(11):2976-83. PubMed ID: 8918495
    [Abstract] [Full Text] [Related]

  • 5. Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial.
    Ravaud A, Chevreau C, Cany L, Houyau P, Dohollou N, Roché H, Soubeyran P, Bonichon F, Mihura J, Eghbali H, Tabah I, Bui BN.
    J Clin Oncol; 1998 Sep; 16(9):2930-6. PubMed ID: 9738560
    [Abstract] [Full Text] [Related]

  • 6. Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: protection at the progenitor cell level.
    Vadhan-Raj S, Broxmeyer HE, Hittelman WN, Papadopoulos NE, Chawla SP, Fenoglio C, Cooper S, Buescher ES, Frenck RW, Holian A.
    J Clin Oncol; 1992 Aug; 10(8):1266-77. PubMed ID: 1634916
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of granulocyte and granulocyte-macrophage colony-stimulating factors in the induction treatment of adult acute lymphoblastic leukemia: a multicenter randomized study.
    Thomas X, Boiron JM, Huguet F, Reman O, Sutton L, Turlure P, Garban F, Gardin C, Espinouse D, Boulat O, Lhéritier V, Fiere D, Groupe d'Etude et de Traitement de la Leucémie Aiguë Lymphoblastique de l'Adulte (GET-LALA Group).
    Hematol J; 2004 Aug; 5(5):384-94. PubMed ID: 15448664
    [Abstract] [Full Text] [Related]

  • 8. Prospective randomized comparison of morning versus night daily single subcutaneous administration of granulocyte-macrophage-colony stimulating factor in patients with soft tissue or bone sarcoma.
    Dinçol D, Samur M, Pamir A, Sencan O, Akbulut H, Yalçin B, Onur H, Demirkazik A, Senler FC, Içli F.
    Cancer; 2000 May 01; 88(9):2033-6. PubMed ID: 10813713
    [Abstract] [Full Text] [Related]

  • 9. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M, Burns LJ, Barker JN, Miller JS, Defor TE, Olujohungbe AB, Weisdorf DJ.
    Biol Blood Marrow Transplant; 2004 Jun 01; 10(6):395-404. PubMed ID: 15148493
    [Abstract] [Full Text] [Related]

  • 10. Granulocyte-macrophage-colony stimulating factor for prevention of neutropenia and infections in children and adolescents with solid tumors. Results of a prospective randomized study.
    Burdach SE, Müschenich M, Josephs W, Frisch J, Schulz G, Jürgens H, Göbel U.
    Cancer; 1995 Aug 01; 76(3):510-6. PubMed ID: 8625134
    [Abstract] [Full Text] [Related]

  • 11. Therapeutic effects and pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor in childhood cancer patients receiving myelosuppressive chemotherapy.
    Furman WL, Fairclough DL, Huhn RD, Pratt CB, Stute N, Petros WP, Evans WE, Bowman LC, Douglass EC, Santana VM.
    J Clin Oncol; 1991 Jun 01; 9(6):1022-8. PubMed ID: 2033415
    [Abstract] [Full Text] [Related]

  • 12. A phase I study of sequential versus concurrent interleukin-3 and granulocyte-macrophage colony-stimulating factor in advanced breast cancer patients treated with FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy.
    O'Shaughnessy JA, Venzon DJ, Gossard M, Noone MH, Denicoff A, Tolcher A, Danforth D, Jacobson J, Keegan P, Miller L, Chow C, Goldspiel B, Cowan KH.
    Blood; 1995 Oct 15; 86(8):2913-21. PubMed ID: 7579383
    [Abstract] [Full Text] [Related]

  • 13. Effects of PIXY321, a granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein, on chemotherapy-induced multilineage myelosuppression in patients with sarcoma.
    Vadhan-Raj S, Papadopoulos NE, Burgess MA, Linke KA, Patel SR, Hays C, Arcenas A, Plager C, Kudelka AP, Hittelman WN.
    J Clin Oncol; 1994 Apr 15; 12(4):715-24. PubMed ID: 8151315
    [Abstract] [Full Text] [Related]

  • 14. Phase I and pharmacokinetic study of recombinant human granulocyte-macrophage colony-stimulating factor given in combination with fluorouracil plus calcium leucovorin in metastatic gastrointestinal adenocarcinoma.
    Grem JL, McAtee N, Murphy RF, Hamilton JM, Balis F, Steinberg S, Arbuck SG, Setser A, Jordan E, Chen A.
    J Clin Oncol; 1994 Mar 15; 12(3):560-8. PubMed ID: 8120554
    [Abstract] [Full Text] [Related]

  • 15. A randomized phase I trial of chronic oral etoposide with or without granulocyte-macrophage colony-stimulating factor in patients with advanced malignancies.
    Shaffer DW, Smith LS, Burris HA, Clark GM, Eckardt JR, Fields SM, Weiss GR, Rinaldi DA, Bowen KJ, Kuhn JG.
    Cancer Res; 1993 Dec 15; 53(24):5929-33. PubMed ID: 8261405
    [Abstract] [Full Text] [Related]

  • 16. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity.
    Gómez H, Mas L, Casanova L, Pen DL, Santillana S, Valdivia S, Otero J, Rodriguez W, Carracedo C, Vallejos C.
    J Clin Oncol; 1998 Jul 15; 16(7):2352-8. PubMed ID: 9667250
    [Abstract] [Full Text] [Related]

  • 17. Use of recombinant human granulocyte colony-stimulating factor to increase chemotherapy dose-intensity: a randomized trial in very high-risk childhood acute lymphoblastic leukemia.
    Michel G, Landman-Parker J, Auclerc MF, Mathey C, Leblanc T, Legall E, Bordigoni P, Lamagnere JP, Demeocq F, Perel Y, Auvrignon A, Berthou C, Bauduer F, Pautard B, Schneider P, Schaison G, Leverger G, Baruchel A.
    J Clin Oncol; 2000 Apr 15; 18(7):1517-24. PubMed ID: 10735900
    [Abstract] [Full Text] [Related]

  • 18. Granulocyte-macrophage colony-stimulating factor given before dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP).
    Holdsworth MT, Roon R, Ferguson J, Martinez L, Stidley CA, Neidhart JA.
    Biotechnol Ther; 1993 Apr 15; 4(3-4):183-95. PubMed ID: 8292969
    [Abstract] [Full Text] [Related]

  • 19. Use of continuous infusion granulocyte-macrophage colony-stimulating factor alone or followed by granulocyte colony-stimulating factor to enhance engraftment following high-dose chemotherapy and autologous bone marrow transplantation for lymphoid malignancies.
    Vose JM, Bierman PJ, Ruby E, Reed EC, Bishop MR, Tarantolo S, Kessinger A, Armitage JO.
    Bone Marrow Transplant; 1996 Jun 15; 17(6):951-6. PubMed ID: 8807099
    [Abstract] [Full Text] [Related]

  • 20. Granulocyte-macrophage colony-stimulating factor in association with high-dose chemotherapy (VETOPEC) for childhood solid tumors: a report from the Australia and New Zealand Children's Cancer Study Group.
    McCowage GB, White L, Carpenter P, Lockwood L, Toogood I, Tiedemann K, Shaw PJ.
    Med Pediatr Oncol; 1997 Aug 15; 29(2):108-14. PubMed ID: 9180912
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.